CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
Status:
RECRUITING
Trial end date:
2031-12-31
Target enrollment:
Participant gender:
Summary
First-line CAR-T-cell consolidation after an abbreviated induction with 2 cycles of Rituximab and Ibrutinib prior to CAR-T-cell treatment and followed by 6 months of maintenance with Ibrutinib in patients with high risk MCL.